Clinical Trial

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

Name: A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours — clinical trial record (NCT06725758)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TEADES

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours

Protocol Amendment History 1 change

notable Trial sites expanded: 1 -> 20 locations 2026-05-09

Trial Details

NCT Number	NCT06725758
Lead Sponsor	Orion Corporation, Orion Pharma
Conditions	Solid Tumours
Enrollment	315 participants
Start Date	2023-10-26
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-08